SHORT MINI-FUTURE - GENMAB | Market Closed - Börse Stuttgart 11:55:55 25/06/2024 am IST | ||
| 25.4 EUR | +0.47% |
|
| Current month | +7.99% | ||
| 1 month | +14.00% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GENMAB A/S
| Date | Price | Change |
|---|---|---|
| 25/24/25 | 25.4 | +0.47% |
| 24/24/24 | 25.28 | -1.13% |
| 20/24/20 | 25.57 | +2.32% |
| 19/24/19 | 24.99 | -0.48% |
| 18/24/18 | 25.11 | +0.36% |
Delayed Quote Börse Stuttgart
Last update June 25, 2024 at 11:55 am IST
More quotesStatic data
| Product type | Certificat Turbo Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | GENMAB A/S |
| Issuer | 
Vontobel
|
| WKN | VQ97WS |
| ISIN | DE000VQ97WS9 |
| Date issued | 04/08/2021 |
| Strike | 3,695 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 14.33 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 25.57 € |
|---|---|
| Lowest since issue | 5.29 € |
Company Profile
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Sector
-
Consensus: Genmab A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
1,799
DKK
Average target price
2,464
DKK
Spread / Average Target
+36.96%
- Stock Market
- Certificates
- Certificat
